Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
KRAKOW, Poland, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
-
KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
-
RVU120 Demonstrates Single-Agent Activity with a Complete Response, 4 Blast Reductions, and 4 Erythroid and/or Platelet responses in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or...
-
Updated Phase Ib data on RVU120 in relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndrome (HR-MDS) to be presented at the 2022 American Society of Hematology (ASH)...
-
Six Presentations Highlight the Clinical and Preclinical Activity of RVU120 and SEL24 (MEN1703) RVU120 Demonstrates Single-Agent Activity with a Complete Response and Disease Stabilization in 10...
-
Updated data from Phase I/II dose-escalation study of RVU120 show four disease stabilizations in advanced solid tumor patients,RVU120 was well tolerated across all doses evaluated,Preclinical data...
-
KRAKOW, Poland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
-
Ryvu Therapeutics, an innovative biotech company, receives EIB financing to accelerate the development of new therapies to treat severe blood cancers and solid tumours, including further clinical...
-
KRAKOW, Poland, July 26, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...